Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$1.91 +4.3%	$1.82	$1.33 ▼ $2.89	$56.45M	1.75	412,266 shs	180,983 shs
MEIP MEI Pharma	$2.84 +18.1%	$2.23	$1.46 ▼ $4.10	N/A	0.19	44,443 shs	53,769 shs
NATR Nature's Sunshine Products	$15.57 +2.6%	$14.29	$10.81 ▼ $18.06	$287.42M	1.14	50,559 shs	38,650 shs
OVID Ovid Therapeutics	$0.34 +4.1%	$0.31	$0.24 ▼ $1.47	$24.46M	0.13	433,003 shs	283,192 shs
SPRO Spero Therapeutics	$2.91 +0.3%	$1.85	$0.51 ▼ $3.09	$162.70M	1.33	1.20 million shs	390,072 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	0.00%	+4.89%	-4.55%	+29.86%	+6.06%
MEIP MEI Pharma	0.00%	+1.25%	+30.05%	+46.89%	+1.25%
NATR Nature's Sunshine Products	0.00%	+7.38%	+7.31%	+35.75%	+4.64%
OVID Ovid Therapeutics	0.00%	+13.91%	+7.97%	+19.49%	-53.86%
SPRO Spero Therapeutics	0.00%	-1.02%	+16.40%	+385.16%	+122.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBIO Fortress Biotech	2.1335 of 5 stars	3.5	1.0	0.0	0.6	3.3	0.6
MEIP MEI Pharma	2.5395 of 5 stars	0.0	5.0	4.2	0.0	0.8	1.3
NATR Nature's Sunshine Products	1.8537 of 5 stars	2.5	3.0	0.0	2.7	2.5	0.0
OVID Ovid Therapeutics	4.2249 of 5 stars	3.6	3.0	4.6	0.6	2.5	0.6
SPRO Spero Therapeutics	3.8971 of 5 stars	3.3	5.0	4.7	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBIO Fortress Biotech	3.00	Buy	$21.00	1,000.05% Upside
MEIP MEI Pharma	2.00	Hold	N/A	N/A
NATR Nature's Sunshine Products	3.00	Buy	$18.33	17.75% Upside
OVID Ovid Therapeutics	3.20	Buy	$3.13	808.43% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	71.82% Upside

Current Analyst Ratings Breakdown

Latest FBIO, NATR, MEIP, SPRO, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	NATR Nature's Sunshine Products	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/7/2025	NATR Nature's Sunshine Products	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/14/2025	NATR Nature's Sunshine Products	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBIO Fortress Biotech	$57.67M	0.98	N/A	N/A	($0.06) per share	-31.82
MEIP MEI Pharma	$65.30M	N/A	$6.30 per share	0.45	$4.96 per share	N/A
NATR Nature's Sunshine Products	$454.36M	0.63	$1.25 per share	12.48	$8.71 per share	1.79
OVID Ovid Therapeutics	$570K	42.92	N/A	N/A	$0.96 per share	0.36
SPRO Spero Therapeutics	$47.98M	3.39	N/A	N/A	$0.85 per share	3.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBIO Fortress Biotech	-$46M	-$2.23	N/A	N/A	N/A	-71.24%	-4,712.53%	-27.67%	8/12/2025 (Estimated)
MEIP MEI Pharma	$17.78M	-$4.75	N/A	N/A	N/A	N/A	-77.00%	-64.79%	9/17/2025 (Estimated)
NATR Nature's Sunshine Products	$7.70M	$0.53	29.38	∞	N/A	2.22%	6.98%	4.63%	8/6/2025 (Estimated)
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)
SPRO Spero Therapeutics	-$68.57M	-$1.28	N/A	N/A	N/A	-156.48%	-123.50%	-58.96%	8/4/2025 (Estimated)

Latest FBIO, NATR, MEIP, SPRO, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	SPRO Spero Therapeutics	-$0.35	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q3 2025	MEIP MEI Pharma	N/A	-$0.39	N/A	-$0.39	N/A	N/A
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
5/13/2025	Q1 2025	SPRO Spero Therapeutics	-$0.55	-$0.25	+$0.30	-$0.25	$11.00 million	$5.87 million
5/6/2025	Q1 2025	NATR Nature's Sunshine Products	$0.16	$0.25	+$0.09	$0.25	$109.39 million	$113.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
MEIP MEI Pharma	N/A	N/A	N/A	N/A	N/A
NATR Nature's Sunshine Products	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBIO Fortress Biotech	1.74	1.72	1.55
MEIP MEI Pharma	N/A	16.78	16.78
NATR Nature's Sunshine Products	N/A	2.41	1.50
OVID Ovid Therapeutics	0.22	4.93	4.93
SPRO Spero Therapeutics	N/A	2.56	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBIO Fortress Biotech	96.51%
MEIP MEI Pharma	52.38%
NATR Nature's Sunshine Products	79.40%
OVID Ovid Therapeutics	72.24%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
FBIO Fortress Biotech	27.90%
MEIP MEI Pharma	3.12%
NATR Nature's Sunshine Products	5.60%
OVID Ovid Therapeutics	13.10%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBIO Fortress Biotech	170	29.57 million	21.32 million	Optionable
MEIP MEI Pharma	100	N/A	N/A	Optionable
NATR Nature's Sunshine Products	850	18.46 million	17.43 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
SPRO Spero Therapeutics	150	55.91 million	52.84 million	Optionable

FBIO, NATR, MEIP, SPRO, and OVID Headlines

Recent News About These Companies

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?

July 1, 2025 | marketbeat.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street Zen

June 21, 2025 | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?

June 19, 2025 | marketbeat.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Up 446.6% in May

June 11, 2025 | marketbeat.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.comF

Spero Therapeutics Shares Soar as Trial with GSK Ends Early on Efficacy

May 28, 2025 | marketwatch.com

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results

May 28, 2025 | msn.com

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28, 2025 | globenewswire.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 13, 2025 | globenewswire.com

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

May 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Russell Rebalance: 3 Stocks Ready to Move Higher
By Chris Markoch | June 20, 2025
View Russell Rebalance: 3 Stocks Ready to Move Higher

FBIO, NATR, MEIP, SPRO, and OVID Company Descriptions

Fortress Biotech NASDAQ:FBIO

$1.91 +0.08 (+4.32%)

As of 07/3/2025 03:36 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

MEI Pharma NASDAQ:MEIP

$2.84 +0.44 (+18.13%)

Closing price 07/3/2025 03:27 PM Eastern

Extended Trading

$2.71 -0.13 (-4.55%)

As of 07/3/2025 04:10 PM Eastern

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Nature's Sunshine Products NASDAQ:NATR

$15.57 +0.40 (+2.64%)

Closing price 07/3/2025 01:04 PM Eastern

Extended Trading

$15.32 -0.25 (-1.60%)

As of 04:23 AM Eastern

Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.

Ovid Therapeutics NASDAQ:OVID

$0.34 +0.01 (+4.08%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$0.35 +0.01 (+1.74%)

As of 04:05 AM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Spero Therapeutics NASDAQ:SPRO

$2.91 +0.01 (+0.34%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$2.95 +0.04 (+1.37%)

As of 05:11 AM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time